Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

BACKGROUND: Patients harbouring the UGT1A1*28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose. However, this dose is considerably lower than the dose that can be tolerated by UGT1A1*1/*1 and *1/*28 patients. This randomised phase II trial evaluated the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Páez, David, Tobeña, María, Fernández-Plana, Julen, Sebio, Ana, Virgili, Anna C., Cirera, Lluís, Barnadas, Agustí, Riera, Pau, Sullivan, Ivana, Salazar, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342907/
https://www.ncbi.nlm.nih.gov/pubmed/30585257
http://dx.doi.org/10.1038/s41416-018-0348-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342907/
https://www.ncbi.nlm.nih.gov/pubmed/30585257
http://dx.doi.org/10.1038/s41416-018-0348-7

Ejemplares similares